首页|期刊导航|时珍国医国药|补肾活血泄浊方调节Keap1/Nrf2/HO-1介导的铁死亡改善慢性肾衰竭大鼠纤维化的机制研究

补肾活血泄浊方调节Keap1/Nrf2/HO-1介导的铁死亡改善慢性肾衰竭大鼠纤维化的机制研究OA

Bushen Huoxue Xiezhuo Formula(补肾活血泄浊方)regulates ferroptosis mediated by Keap1/Nrf2/HO-1 to reduce renal fibrosis in rats with chronic renal failure

中文摘要英文摘要

目的 观察补肾活血泄浊方(BHXF)对慢性肾衰竭(CRF)模型大鼠的效果,探究Keap1/Nrf2/HO-1介导的铁死亡的抗肾脏纤维化机制.方法 随机将90只雄性SD大鼠分为假手术组、模型组、BHXF低剂量组(5.31g·kg-1·d-1)、BHXF中剂量组(10.62g·kg-1·d-1)、BHXF高剂量组(21.24g·kg-1·d-1)、贝那普利组(10mg·kg-1·d-1)、每组均为15只.分别给予相应剂量的BHXF,假手术组和模型组则灌胃等体积生理盐水,每天1次,连续8周.实验结束后,收集大鼠肾脏组织进行HE、Masson染色,光镜下观察肾脏组织损伤和纤维化程度;全自动生化仪检测血清中Urea、Scr、β2-MG;酶联免疫吸附法(ELISA)检测血清中ROS、SOD、MDA;免疫组织化学法(IHC)检测肾脏组织中α-SMA,TGF-β、FN、Collagen-1、SLC7A11、GPX4的表达;免疫组织印迹法(Western blot)检 测:Keap1、Nrf2、HO-1;实时定量反转录 PCR(Real-time RT-PCR)检测 Keap1、Nrf2、HO-1、SLC7A11、GPX4的mRNA表达.结果 相比于假手术组,模型组大鼠肾脏出现了肾小管明显扩张、胶原沉积等典型的病理改变;Urea、SCr、β2-MG、ROS、MDA、α-SMA,TGF-β、FN、Collagen-1、Keap1表达升高(P<0.05);SOD、Nrf2、HO-1、GPX4、SLC7A11表达降低(P<0.05);药物干预后,各组病理改变及纤维化减轻(P<0.05);Urea、SCr、β2-MG、ROS、MDA、α-SMA,TGF-β、FN、Collagen-1、Keap1表达降低(P<0.05);SOD、Nrf2、HO-1、GPX4、SLC7A11表达升高(P<0.05);以BHXF高剂量组效果最佳(P<0.05).结论 BHXF有效抑制了肾脏纤维化,改善了肾脏功能,其潜在机制可能与Keap1/Nrf2/HO-1轴抑制铁死亡途径有关.

Objective To evaluate the effects of Bushen Huoxue Xiezhuo Formula(补肾活血泄浊方,BHXF)in a rat model of chronic renal failure(CRF)and investigate its potential anti-renal fibrosis mechanism related to the ferroptosis pathway mediated by Keap1/Nrf2/HO-1.Methods Ninety male SD rats were randomly divided into six groups(n=15 per group):the sham-operated group,model group,low/medium/high-dose BHXF group(5.31 g·kg-1·d-1,10.62 g·kg-1·d-1,21.24 g·kg-1·d-1),and the benazepril group(10 mg·kg-1·d-1).Rats received the corresponding doses of BHXF or benazepril by gavage once daily for 8 weeks;the sham-operated and model groups received an equivalent volume of physiological saline.After the experiment,kidney tissues were collected for histological exami-nation(HE and Masson staining)to assess renal injury and fibrosis under light microscopy.Serum levels of urea nitrogen(Urea),serum creatinine(SCr),and β2-MG were measured using an automated biochemical analyzer.Serum ROS,SOD,and MDA levels were detected by ELISA.Immunohistochemistry(IHC)was used to detect the expression of α-SMA,TGF-β,FN,Collagen-I,SLC7A11,and GPX4 in renal tissues.Western blot(WB)was performed to analyze the protein expression of Keap1,Nrf2,and HO-1.The mRNA expression levels of Keap1,Nrf2,HO-1,SLC7A11,and GPX4 were quantified by real-time reverse transcription poly-merase chain reaction(RT-PCR).Results Compared with the sham-operated group,the model group exhibited significant pathological alterations,including marked renal tubular dilation and collagen deposition.The model group also showed increased levels of Urea,SCr,β2-MG,ROS,MDA,α-SMA,TGF-β,FN,Collagen-I,and Keap1 protein(P<0.05),alongside decreased levels of SOD,Nrf2 protein,HO-1 protein,GPX4 protein,and SLC7A11 protein(P<0.05).Drug interventions ameliorated the pathological changes and reduced fibrosis(P<0.05).Treated groups exhibited decreased levels of Urea,SCr,β2-MG,ROS,MDA,α-SMA,TGF-β,FN,Collagen-I,and Keap1 protein(P<0.05),and increased levels of SOD,Nrf2 protein,HO-1 protein,GPX4 protein,and SLC7A11 protein(P<0.05).The high-dose BHXF group demonstrated the most pronounced effects(P<0.05).Conclusion BHXF effectively attenuated renal fibrosis and improved renal function in CRF rats.Its underlying mechanism may involve regulating the Keap1/Nrf2/HO-1 signaling pathway to inhibit ferroptosis.

吴振华;刘靖薇;王欣冉;闫晓欢;檀淼;陈素枝;檀金川;杨凤文;任美芳

河北中医药大学,河北 石家庄 050200河北中医药大学,河北 石家庄 050200河北中医药大学,河北 石家庄 050200河北中医药大学,河北 石家庄 050200河北医科大学第四医院,河北 石家庄 050000河北省中医院,河北 石家庄 050011河北省中医院,河北 石家庄 050011河北省中医院,河北 石家庄 050011河北省中医院,河北 石家庄 050011

医药卫生

慢性肾衰竭补肾活血泄浊方铁死亡纤维化Keap1/Nrf2/HO-11通路

Chronic renal failureBushen Huoxue Xiezhuo Formula(补肾活血泄浊方)FerroptosisFibrosisKeap1/Nrf2/HO-1 pathway

《时珍国医国药》 2026 (8)

1439-1447,9

国家自然科学基金(82405075)河北省自然科学基金(2021423050)河北省政府优才项目(ZF2024165)国家中医临床研究基地项目河北省脾肾病证中医治疗技术创新中心项目

10.70976/j.1008-0805.SZGYGY-2026-0805

评论